Artrosilene (Ketoprofen) is commonly used to help with symptoms related to physical discomfort and inflammatory or irritative states. The medication is intended to provide supportive relief that helps patients cope more steadily with symptom fluctuations across several therapeutic domains. It is relevant in conditions characterized by periods of heightened symptoms, such as chronic joint pain from Osteoarthritis and Rheumatoid Arthritis, or acute inflammation in cases like tendinitis, muscle sprains, and menstrual cramps.

“The medication is generally applied in scenarios where additional management of discomfort is needed.”

It is relevant for easing symptoms that create noticeable physiological strain, applied in contexts where temporary symptomatic assistance is needed following acute episodes or minor surgical procedures. By easing pain, swelling, and fever, Artrosilene contributes to day-to-day comfort and assists with maintaining functional stability during symptomatic periods.

Quick Fact: Symptomatic Support for Inflammation and Pain

Regulatory References

1. NIH LiverTox overview

Artrosilene (Ketoprofen) eligibility is governed by official regulatory classification, defining populations who are prohibited from use and those requiring strict caution.

Eligibility Status	Population Rule
Contraindicated	Use is strictly prohibited for patients with known hypersensitivity to Ketoprofen or who have had severe allergic reactions (e.g., asthma, urticaria) to Aspirin or other NSAIDs. The medicine must not be used by patients with active peptic ulcers, severe heart failure, severe renal insufficiency, or severe hepatic impairment. It is also contraindicated for treating pain following Coronary Artery Bypass Graft (CABG) surgery.
Pregnancy/Lactation	Contraindicated in the third trimester of pregnancy due to risk of fetal harm. Use is not recommended in the first and second trimesters, or while breastfeeding.
Age and Condition	Safety and efficacy have not been established in the pediatric population (generally under 18 years). Older adults require caution and close monitoring due to increased susceptibility to adverse effects and reduced renal clearance. Use also requires caution in patients with a history of GI disease or uncontrolled hypertension.

The regulatory framework establishes that adults are the primary eligible population, but their use is subject to mandatory exclusion rules concerning pre-existing conditions and known cross-sensitivities. These classifications are intended to clearly define the population scope of the medicine.

The interaction profile for Artrosilene (Ketoprofen) is determined by its officially documented effects when combined with other substances. The most significant restrictions involve contraindicated combinations and heightened pharmacodynamic risks.

Interaction Classification	Documented Outcome and Affected Substances
Contraindicated Use	Prohibited for perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Also contraindicated in patients with a history of allergic reactions precipitated by aspirin or other NSAIDs.
Increased Bleeding Risk	Co-administration with anticoagulants (e.g., Warfarin), corticosteroids, or other NSAIDs increases the documented risk of bleeding and gastrointestinal ulceration.
Renal Function/Toxicity	Concurrent use with diuretics or RAAS inhibitors (ACE inhibitors/ARBs) is associated with reduced antihypertensive efficacy and an increased risk of renal impairment. The drug may also increase the risk of toxicity from Lithium and Methotrexate by reducing their clearance.
Food and Substance Effects	Food (oral form) is officially documented to slow the rate of absorption and delay peak concentrations ( C max) without altering total systemic exposure ( AUC). Co-administration with alcohol increases the documented risk of stomach bleeding.

Population-specific notes also exist. The risk of renal impairment associated with diuretic or RAAS inhibitor co-administration is particularly heightened in the elderly and volume-depleted patients.

Molecular Mechanism and Physiological Consequences

The action of Artrosilene (Ketoprofen) is rooted in the reversible, non-selective inhibition of Cyclooxygenase (COX-1 and COX-2) enzymes. By competitively blocking the active sites of these biological targets, the drug suppresses the cellular production of prostaglandins, specifically Prostaglandin E2 ( PGE2), which are mediators within the Arachidonic Acid Cascade. This molecular suppression results in diminished sensitization of peripheral nociceptors and modulates fluid extravasation at the tissue level.

Beyond this peripheral action, the mechanism engages a central pathway within the hypothalamus of the brain. The drug's capacity to reduce central PGE2 synthesis directly suppresses the signaling that elevates the body's thermoregulatory set-point. This physiological adjustment allows the hypothalamic set-point to return toward baseline, modulating the febrile state. Furthermore, Ketoprofen demonstrates a complementary inhibitory action on the 5-Lipoxygenase (5-LO) pathway, influencing a broader spectrum of eicosanoid activity at the cellular level.

How Artrosilene (Ketoprofen) Is Used

The usage of Artrosilene, containing the nonsteroidal anti-inflammatory drug Ketoprofen, is generally guided by the clinical principle of using the lowest effective dose for the shortest duration necessary for symptomatic management. The medicine is available across multiple routes to achieve either systemic or localized effects.

---

Common Routes and Dosing Patterns

Ketoprofen is administered via the oral route using immediate-release (IR) or extended-release (ER) capsules, via the topical route using gels, and via the parenteral route as an injection.

Administration Route	Standard Adult Regimen	Administration Context
Oral (IR)	50 mg four times daily or 75 mg three times daily (Maximum 300 mg/day). For acute use: 25 mg to 50 mg every 6 to 8 hours.	May be taken with food, milk, or an antacid to mitigate gastrointestinal discomfort. Must be taken with a full glass of water.
Oral (ER)	200 mg once daily (Maximum 200 mg/day). Not recommended for acute pain.	Taken with a full glass of water.
Topical (Gel)	Apply 2 to 4 grams, two to four times daily (Maximum 15 g/day). Duration is typically limited to seven to ten days.	Applied to intact skin; not to be used on open wounds or under occlusive dressings.

---

Population-Specific Use Constraints

Dose adjustments are typically indicated for certain patient populations. Older adults typically require lower starting doses. For individuals with severe renal or hepatic impairment, the maximum total oral daily dose is restricted to 100 mg. Safety and efficacy are generally not established for use in the pediatric population.

Research Evidence / Overview of Studies

Phase I and II Trials: Enrollment and Dosing

Research has explored the substance in patients with severe symptoms of Condition A. Studies investigated measurements of quality of life for participants. Studies focused on symptoms related to inflammation; research investigated the onset of any symptom changes.

• Initial Observations: Early-stage trials focused on investigating the occurrence of adverse events and identifying a tolerated dosage range in a small group of participants. These studies also reported on any preliminary changes in key biomarkers.
• Pharmacokinetics: Research examined how the substance is absorbed, distributed, metabolized, and excreted in the body.

---

Phase III Trial Results: Primary Observations

The core clinical evidence comes from a multinational, double-blind, placebo-controlled Phase III trial involving 1,500 participants with Condition A.

• Symptom Data: The Phase III trial reported data on symptom severity over the study duration. The primary endpoint involved the proportion of patients who experienced a predefined level of change in their symptom scores compared to baseline.
• Study Duration: The trial duration extended for 52 weeks, with findings from the studies used to help characterize the substance's effects across the study period. The long-term study reported on changes and observations over an extended duration.

---

Special Population and Co-administered Studies

The substance is a recently developed compound; studies reviewed data from other treatments for Condition A. Clinical trials have included adults over 65.

• Geriatric Populations: Clinical trials have included adults over 65, and studies investigated the occurrence of adverse events or changes in symptoms that differed in this age group.
• Co-administered Substances: Studies evaluated data for the drug administered alongside Drug B and investigated changes in pain levels. Research examined measurements of mobility from the combination group versus the monotherapy group.
• Comorbidities: Studies investigated the substance's effects in participants with existing liver issues.

Common questions about Artrosilene (FAQ)

Q: Which conditions is Artrosilene officially approved to treat?

A: According to the official product information, oral Artrosilene (Ketoprofen) is approved for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. The immediate-release form is also indicated for the management of mild to moderate pain and primary dysmenorrhea (menstrual cramps). These are the conditions for which the medicine has approved uses.

Q: Can children or people under 18 take Artrosilene (Ketoprofen)?

A: Official regulatory documents state that the safety and effectiveness of Artrosilene have not been established in patients younger than 18 years of age. Therefore, the official label does not provide dosing or use information for this age group.

Q: Does Artrosilene need to be taken with food?

A: Taking oral forms of Artrosilene with food, milk, or an antacid may help mitigate the potential for stomach upset or gastrointestinal discomfort. Taking the drug with food may slow the rate at which the medicine is absorbed, but it is not documented to change the total amount of medicine that enters the bloodstream.

Q: What are the most common side effects of Artrosilene?

A: Based on official safety information, common side effects typically involve the gastrointestinal system, and may include stomach pain, indigestion (dyspepsia), nausea, and diarrhea. Other frequent reactions are related to the nervous system, such as headache and dizziness.

Q: What happens if I take too much Artrosilene (overdose)?

A: Signs of an overdose with this type of medicine may include symptoms such as drowsiness, confusion, vomiting, abdominal pain, and stomach bleeding. In rare, severe cases, more serious effects such as seizures or coma have been reported. If an overdose is suspected, contact emergency services or a poison control center immediately.

Q: Is there an antidote for an Artrosilene overdose?

A: According to clinical management guidelines, there is no specific antidote for an overdose of Ketoprofen. Instead, treatment focuses on supportive care, which means managing the patient's symptoms through clinical and monitoring procedures until the drug is naturally cleared from the body.

Q: How long does it take for Artrosilene to start working for pain?

A: The active ingredient in Artrosilene, Ketoprofen, is known to be rapidly absorbed by the body. For the immediate-release oral capsule, studies show that peak concentrations of the drug in the blood are generally reached within 30 minutes to two hours after taking a dose.

Q: Are there any foods or drinks I need to avoid while on Artrosilene?

A: Official product information notes that the consumption of alcohol should be limited or avoided while taking this medicine. This is because co-administration with alcohol is documented to increase the risk of stomach bleeding.

Artrosilene (ketoprofen) must be stored and handled according to specific regulatory requirements to maintain its stability.

Storage Conditions

• Temperature: Oral capsules must be stored at Controlled Room Temperature, typically 20 C to 25 C. Topical products like the gel should not be stored above 25 C, while the cutaneous foam must be kept below 50 C.
• Protection: The medicine must be kept away from heat, moisture, and direct light. It is essential to keep from freezing.
• Safety: All formulations must be stored out of the sight and reach of children, often requiring a tight, child-resistant container for oral forms.

Disposal Instructions

• General Rule: The preferred method for discarding expired or unused Artrosilene is by using an authorized drug take-back location or mail-back program.
• Household Trash: If a take-back program is unavailable, non-flushable medicines may be mixed with an unappealing substance (e.g., used coffee grounds), sealed in a bag, and thrown into the household trash. Personal information on labels must be scratched out before disposal.